Fram R J, Skarin A T, Rosenthal D S, Pinkus G, Nadler L M
Cancer. 1983 Oct 1;52(7):1220-8. doi: 10.1002/1097-0142(19831001)52:7<1220::aid-cncr2820520716>3.0.co;2-g.
A retrospective review of 34 patients with non-Hodgkin's lymphoma and a leukemic phase was undertaken. The median survival after onset of a leukemic phase was 30 months for patients with nodular poorly differentiated lymphocytic lymphoma which was significantly longer than 19 months for diffuse poorly differentiated lymphocytic lymphoma, and 2 months for diffuse histiocytic and undifferentiated lymphoma. Clinical features of patients with diffuse histologies that contributed to a poor prognosis included advanced stage of disease as well as age. Underlying lymph node histology also defined features of the leukemic phase which included duration, peak leukocyte count, and in some instances, distinctive morphologic characteristics of circulating malignant cells. Although small sample size did not permit definitive correlations of immunological subtype and survival, heterogeneity was noted, suggesting that clearer stratification of these patients with immunologic techniques may be useful in assessing prognosis in future investigations.
对34例非霍奇金淋巴瘤伴白血病期患者进行了回顾性研究。结节性低分化淋巴细胞淋巴瘤患者白血病期发病后的中位生存期为30个月,显著长于弥漫性低分化淋巴细胞淋巴瘤的19个月以及弥漫性组织细胞性和未分化淋巴瘤的2个月。弥漫性组织学类型患者预后不良的临床特征包括疾病晚期和年龄。潜在的淋巴结组织学也确定了白血病期的特征,包括持续时间、白细胞计数峰值,在某些情况下还包括循环恶性细胞的独特形态特征。尽管样本量小不允许确定免疫亚型与生存之间的明确相关性,但仍注意到存在异质性,这表明在未来的研究中,用免疫技术对这些患者进行更清晰的分层可能有助于评估预后。